Table 3.
Comparison of surviving and non-surviving convalescent plasma recipients.
| Survivor | Non-survivor | p | |
|---|---|---|---|
| n | 10 | 5 | |
| Male (%) | 8 (80.0) | 5 (100.0) | 0.524 |
| Age (median [range]) – years old | 46 [28–72] | 60 [50–88] | 0.057 |
| Blood group (%) | 0.364 | ||
| O | 6 (60.0) | 1 (20.0) | |
| B | 4 (40.0) | 3 (60.0) | |
| AB | 0 (0.0) | 1 (20.0) | |
| Comorbid number (%) | 0.248 | ||
| 0 | 3 (30.0) | 0 (0.0) | |
| 1 | 4 (40.0) | 1 (20.0) | |
| 2 | 1 (10.0) | 1 (20.0) | |
| 3 | 2 (20.0) | 1 (20.0) | |
| 4 | 0 (0.0) | 2 (40.0) | |
| Body weight (median [range]), kg | 67.50 [60–100] | 60 [55–101] | 0.264 |
| Severe COVID-19 (%) | 8 (80.0) | 4 (80.0) | 1 |
| Tranfusion onset (median [range]) | 3.50 [1–20] | 3 [2–6] | 0.901 |
| Baseline parameter | |||
| Temperature (median [range]) | 36.5 [36–37] | 36.7 [36–36.9] | 0.496 |
| Ct value (median [range]) | 30.88 [7.78–38.39] | 25.91 [17.69–35.75] | 0.391 |
| SOFA (median [range]) | 2 [0–4] | 3 [0–6] | 0.187 |
| PaO2/FiO2 ratio (median [range]) | 265.90 [92.20–553.30] | 101.70 [62.10–660.5] | 0.221 |
| WBC (median [range]) | 9.21 [5.27–12.30] | 11.41 [6.11–29.10] | 0.244 |
| ANC (median [range]) | 6.08 [0.87–11.40] | 10.32 [4.90–26.77] | 0.086 |
| ALC (median [range]) | 0.79 [0.39–1.78] | 0.71 [0.29–2.01] | 0.759 |
| NLR (median [range]) | 9.45 [1–18.50] | 16.50 [2.60–92.30] | 0.27 |
| LMR (median [range]) | 2 [0.80–4.5] | 1.40 [1–1.90] | 0.086 |
| IL-6(median [IQR]) | 8.30 [1.50–219.80] | 25.47 [10.73–2104] | 0.176 |
| CRP (median [range]) | 39 [5–122] | 150 [5–150] | 0.154 |
| Procalcitonin (median [range]) | 0.05 [0.05–0.21] | 0.60 [0.05–0.90] | 0.02 |
| D-Dimer (median [range]) | 431.5 [216–1730] | 1483 [617–5670] | 0.02 |
| Creatinin (median [range]) | 0.95 [0.49–1.58] | 0.89 [0.72–2.76] | 0.806 |
| ALT/SGPT (median [range]) | 51 [22–406] | 32 [19–309] | 0.386 |
| AST/SGOT (median [range]) | 50 [19–295] | 30 [23–338] | 0.593 |